29 August 2017 - The U.S. FDA today approved Vabomere for adults with complicated urinary tract infections, including a type of kidney infection, pyelonephritis, caused by specific bacteria. 

Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria.

The safety and efficacy of Vabomere were evaluated in a clinical trial with 545 adults with cUTI, including those with pyelonephritis. At the end of intravenous treatment with Vabomere, approximately 98% of patients treated with Vabomere compared with approximately 94% of patients treated with piperacillin/tazobactam, another antibacterial drug, had cure/improvement in symptoms and a negative urine culture test. Approximately seven days after completing treatment, approximately 77% of patients treated with Vabomere compared with approximately 73% of patients treated with piperacillin/tazobactam had resolved symptoms and a negative urine culture.

Read FDA press release